Skip to main content


Page 11 of 11

  1. Chronic kidney disease (CKD) is an independent risk factor for cardiovascular disease and also increases the incidence of cerebrovascular disease. Prevention and management of cerebrovascular disease in patien...

    Authors: Kazuhiko Tsuruya and Kiichiro Fujisaki
    Citation: Renal Replacement Therapy 2016 2:29
  2. It is generally accepted that renal hypoxia plays an important role in the progression of chronic kidney disease (CKD). This review focuses on renal hypoxia and hypoxia-inducible factor (HIF), a master regulat...

    Authors: Shinji Tanaka, Tetsuhiro Tanaka and Masaomi Nangaku
    Citation: Renal Replacement Therapy 2016 2:25
  3. Dipeptidyl peptidase-4 inhibitors (DPP-4i) have become widely used in hemodialysis patients with type 2 diabetes mellitus (T2DM). This study aimed at testing the hypothesis that administration of alogliptin, a...

    Authors: Shinya Kawamoto, Ryo Koda, Yuji Imanishi, Atsunori Yoshino and Tetsuro Takeda
    Citation: Renal Replacement Therapy 2016 2:39
  4. Erythropoiesis-stimulating agents, for example epoetin beta pegol which is a continuous erythropoietin receptor activator (CERA), and darbepoetin alfa (DPO), are recently introduced into clinical practice for ...

    Authors: Jun Sawa, Masaaki Inaba, Koichi Noguchi, Chie Nakagawa, Mayuko Kuwamura, Yukinobu Kuwamura, Noritsugu Wada, Kayoko Kitatani, Yuji Kawaguchi and Yasuro Kumeda
    Citation: Renal Replacement Therapy 2016 2:26
  5. The annual incidence of acute kidney injury (AKI) has been increasing as the population ages. Despite advances in critical care and dialysis technology, the mortality remains unacceptably high in patients with...

    Authors: Shigeo Negi, Daisuke Koreeda, Sou Kobayashi, Yu Iwashita and Takashi Shigematu
    Citation: Renal Replacement Therapy 2016 2:31
  6. Adverse reactions, such as anaphylactoid shock, have been reported to occur frequently with the use of polysulfone (PSf) membrane dialyzers. Polyvinylpyrrolidone (PVP) elution from the membrane may be a key fa...

    Authors: Jun Murakami, Iwakazu Kaneko, Naoki Kimata, Michio Mineshima and Takashi Akiba
    Citation: Renal Replacement Therapy 2016 2:36
  7. Inguinal hernia is common in dialysis patients, especially peritoneal dialysis (PD) patients; however, no previous reports have assessed the incidence, type, treatments, and risk factors of inguinal hernia in ...

    Authors: Masataka Banshodani, Hideki Kawanishi, Misaki Moriishi, Sadanori Shintaku, Shinji Hashimoto and Masahiro Nishihara
    Citation: Renal Replacement Therapy 2016 2:24
  8. Kocuria kristinae is an aerobic Gram-positive coccus that is considered ubiquitous and non-pathogenic in healthy individuals. Furthermore, only 27 reports have described cases of criti...

    Authors: Taro Horino, Yoshiko Shimamura, Koji Ogata, Kosuke Inoue and Yoshio Terada
    Citation: Renal Replacement Therapy 2016 2:32
  9. Guidelines have recommended that physicians screen for coronary artery disease (CAD) at the initiation of dialysis. The purpose of this study was to examine the effects of CAD screening at the initiation of di...

    Authors: Yuri Tanaka, Nobuhiko Joki, Toshihide Hayashi, Masaki Iwasaki, Shun Kubo, Takasuke Asakawa, Ai Matsukane, Mari Horie, Yasunori Takahashi, Hiroki Niikura, Koichi Hirahata, Yoshihiko Imamura and Hiroki Hase
    Citation: Renal Replacement Therapy 2016 2:22
  10. Pruritus in hemodialysis patients is a serious complication that lowers quality of life and adversely affects survival. Hemodialysis-associated pruritus has multiple causes and treatments; however, no effectiv...

    Authors: Naoko Takahashi, Taku Yoshizawa, Junko Kumagai, Hideki Kawanishi, Misaki Moriishi, Takao Masaki and Shinichiro Tsuchiya
    Citation: Renal Replacement Therapy 2016 2:27
  11. Fibroblast growth factor 23 (FGF23) is a bone-derived hormone regulating phosphate and vitamin D metabolism. FGF23 works by binding to Klotho-FGF receptor (FGFR) complex. FGF23 reduces serum phosphate level by...

    Authors: Yuichi Takashi and Seiji Fukumoto
    Citation: Renal Replacement Therapy 2016 2:20
  12. In chronic kidney disease (CKD), the patients on a low-protein diet are considered to be at high risk of protein-energy wasting. Furthermore, a low-protein diet conceivably results in reduced intake of various...

    Authors: Yoshie Kanazawa, Shunsuke Morita, Hirofumi Sonoki and Toshiyuki Nakao
    Citation: Renal Replacement Therapy 2016 2:18
  13. Lanthanum carbonate (LC), an effective phosphate (P) binder, is widely used to manage hyperphosphatemia in hemodialysis patients. However, the long-term safety of LC treatment in clinical practice has not been...

    Authors: Takashi Shigematsu, Shigeo Negi and Masaki Ohya
    Citation: Renal Replacement Therapy 2016 2:30
  14. Linagliptin, the only bile-excreted dipeptidyl peptidase-4 (DPP-4) inhibitor, is a therapeutic drug for patients with diabetes receiving hemodialysis, for whom inflammation is a prognosis-related factor, becau...

    Authors: Yuya Nakamura, Hitomi Hasegawa, Mayumi Tsuji, Tatsunori Oguchi, Masatomo Mihara, Hiroki Suzuki, Kazumasa Nishida, Michiyasu Inoue, Tatsuo Shimizu, Isao Ohsawa, Hiromichi Gotoh, Yoshikazu Goto, Masahiro Inagaki and Katsuji Oguchi
    Citation: Renal Replacement Therapy 2016 2:17
  15. Diabetic nephropathy (DN) not only is a major cause of end-stage renal disease (ESRD) in developing and developed countries but also plays a critical role as a risk factor for cardiovascular disease. The patho...

    Authors: Daiji Kawanami, Keiichiro Matoba and Kazunori Utsunomiya
    Citation: Renal Replacement Therapy 2016 2:16
  16. Activation of vitamin D is severely impaired in patients with advanced stages of chronic kidney disease, particularly those on hemodialysis. Observational studies have shown that the use of vitamin D receptor ...

    Authors: Tetsuo Shoji, Masaaki Inaba and Yoshiki Nishizawa
    Citation: Renal Replacement Therapy 2016 2:19
  17. Many issues regarding the management of renal replacement therapy (RRT) in acute kidney injury (AKI) including timing of initiation, selection of RRT modality, and optimal dosing remain to be resolved. Two maj...

    Authors: Teruhiko Yoshida, Yohei Komaru, Ryo Matsuura, Yoshihisa Miyamoto, Kohei Yoshimoto, Eisei Noiri, Masaomi Nangaku, Naoki Yahagi and Kent Doi
    Citation: Renal Replacement Therapy 2016 2:13
  18. In chronic kidney disease patients, angiotensin receptor blockers (ARBs) have been known to increase serum potassium (K) levels. On the other hand, it has been reported that in patients on maintenance dialysis...

    Authors: Kiyotsugu Omae, Tetsuya Ogawa, Masao Yoshikawa, Hiroshi Sakura and Kosaku Nitta
    Citation: Renal Replacement Therapy 2016 2:14
  19. The baseline levels of serum procalcitonin (PCT) have not been determined in patients with end-stage renal disease needing renal replacement therapy. The purpose of the present study is to verify the reference...

    Authors: Koji Ichihara, Toshiaki Tanaka, Satoshi Takahashi, Masanori Matsukawa, Masahiro Yanase, Hiroshi Kitamura and Naoya Masumori
    Citation: Renal Replacement Therapy 2016 2:9
  20. Needle insertion pain associated with maintenance hemodialysis (HD) causes considerable stress on HD patients with native arteriovenous fistula. Skin cooling has been suggested to modify pain sensitivity and r...

    Authors: Toshihiro Torato, Masao Iwagami, Hiroshi Kawaguchi, Toshiaki Suzuki, Noriyuki Yamamoto, Shigeki Matsuo, Chiduru Ishikawa, Daisuke Katagiri, Yoshifumi Hamasaki, Norio Hanafusa, Masaomi Nangaku, Tsutomu Sanaka and Eisei Noiri
    Citation: Renal Replacement Therapy 2016 2:6
  21. Hemodialysis (HD) patients who are resistant to erythropoiesis-stimulating agents (ESAs) have a higher mortality rate. The aim of this study was to assess the relationship between the time-dependent variabilit...

    Authors: Shunji Shiohira, Ken Tsuchiya, Hiroshi Kataoaka, Masayuki Okazaki, Mizuki Komatsu, Toshiaki Naganuma, Hiroshi Kawaguchi and Kosaku Nitta
    Citation: Renal Replacement Therapy 2016 2:10
  22. The goal of the present study was to explore the differences in effects between erythropoiesis-stimulating agent (ESA) types on hemoglobin (Hb) level at the initiation of maintenance dialysis.

    Authors: Takasuke Asakawa, Yasuhiro Komatsu, Ryoichi Ando, Nobuhiko Joki, Yuri Tanaka, Masaki Iwasaki, Hiroki Hase, Masato Ikeda, Daijo Inaguma, Toshifumi Sakaguchi, Toshio Shinoda, Fumihiko Koiwa, Shigeo Negi, Toshihiko Yamaka and Takashi Shigematsu
    Citation: Renal Replacement Therapy 2016 2:12
  23. Because hemodialysis therapy cannot be performed without the cannulation of a vascular access, establishing a well-functioning vascular access is crucial. Recently, the number of patients with difficult arteri...

    Authors: Tadashi Kamata, Mayumi Tomita and Noriyuki Iehara
    Citation: Renal Replacement Therapy 2016 2:7
  24. Japan has relatively low incidence rates of renal replacement therapy (RRT) for end-stage kidney disease (ESKD) among those aged 0–19 years, but relatively high rates for the older age band. On the other hand,...

    Authors: Minako Wakasugi, Junichiro James Kazama and Ichiei Narita
    Citation: Renal Replacement Therapy 2016 2:5
  25. Glycated albumin (GA) has been reported to be a better indicator of glycemic control than hemoglobin A1c (HbA1c) in diabetic hemodialysis (HD) patients.

    Authors: Yuki Tsuruta, Akiko Ichikawa, Kan Kikuchi, Yoshihisa Echida, Takako Onuki and Kosaku Nitta
    Citation: Renal Replacement Therapy 2016 2:3
  26. Peritonitis is the main cause of withdrawal from peritoneal dialysis (PD) therapy in Japan. The precise extent of PD-associated peritonitis in Japan has not been investigated since 2005; we aimed to clarify th...

    Authors: Chieko Higuchi, Minoru Ito, Ikuto Masakane and Hiroshi Sakura
    Citation: Renal Replacement Therapy 2016 2:2
  27. Perirenal hematomas are most frequently caused by neoplasm, followed by polyarteritis nodosa (PN), but may also be a rare complication of MPA.

    Authors: Yuri Nakashima, Maki Ohura, Toru Mima, Asuka Masumoto, Masaki Ohya, Shigeo Negi and Takashi Shigematsu
    Citation: Renal Replacement Therapy 2015 1:8
  28. The nutritional status of patients on maintenance hemodialysis (MHD) is a strong predictor of their survival. We assessed the reliability of a protein-energy wasting (PEW) score as a predictor of the survival ...

    Authors: Sonomi Kobayashi, Keiko Suzuki, Mio Ueda, Yoshiko Tanaka and Kosaku Nitta
    Citation: Renal Replacement Therapy 2015 1:1
  29. In blood purification therapies for critical care, there are no guidelines for selecting modalities of the treatment or for determining the treatment schedule, treatment time, and operating conditions, such as...

    Authors: Michio Mineshima
    Citation: Renal Replacement Therapy 2015 1:5
  30. As a result of the advances in computers, data collection has become easy. The huge amount of data now available through computers is called big data. The characteristics of big data are represented by three V...

    Authors: Eiichiro Kanda
    Citation: Renal Replacement Therapy 2015 1:4
  31. There may be an association between the responsiveness to erythropoiesis-stimulating agent (ESA) and the nutritional status on mortality of maintenance hemodialysis (MHD) patients. Therefore, we assessed the a...

    Authors: Masayuki Okazaki, Mizuki Komatsu, Shunji Shiohira, Hiroshi Kataoka, Ken Tsuchiya, Hiroshi Kawaguchi and Kosaku Nitta
    Citation: Renal Replacement Therapy 2015 1:7
  32. Only 4 % of hemodialysis (HD) patients survive over 25 years after their initiation of HD even in Japan. To elucidate their clinical characteristics, we investigated their lifestyle and genetic factor. TT geno...

    Authors: Kaori Sakamoto, Yoshihiko Kanno, Mami Hiraoka, Matsuhiko Hayashi, Yoshiko Kontai and Yasuo Kagawa
    Citation: Renal Replacement Therapy 2015 1:6
  33. L-carnitine is an essential compound that facilitates the transport of long-chain fatty acid across the inner mitochondrial membrane for β-oxidation. However, the effect of L-carnitine supplementation remains ...

    Authors: Haruki Sada, Akihiko Kato, Ryo Sumimoto, Hiromitsu Ohmori and Hideki Ohdan
    Citation: Renal Replacement Therapy 2015 1:3

Annual Journal Metrics

  • 2022 Citation Impact
    1.2 - 2-year Impact Factor
    0.703 - SNIP (Source Normalized Impact per Paper)
    0.438 - SJR (SCImago Journal Rank)

    2023 Speed
    12 days submission to first editorial decision for all manuscripts (Median)
    137 days submission to accept (Median)

    2023 Usage 
    139 Altmetric mentions